Japan's Chugai, Bioventure to Co-Develop Antibody Drugs (Japan)
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical Co. has signed an agreement for the collaborative development of antibody drugs with bioventure Chiome Bioscience Inc., which has a proprietary technology using chicken immunocytes grown in cultures to create antibodies in just a week, compared with the months it ordinarily takes using lab animals. Chugai has already commercialized one antibody drug, and wants to use Chiome's technologies to develop antibodies against a variety of disease marker proteins. The antibodies will form the material basis enabling Chugai to develop other antibody drugs, with a focus on diagnostics and therapeutics for cancers and immune disorders. (Print Edition Only: Link to Full Text Unavailable